Skip to content

Effect of Acupuncture on Patient Vulvodynia Outcomes

Double-blind Phase 2 RCT: Effect of Acupuncture on Patient Vulvodynia Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03364127
Enrollment
89
Registered
2017-12-06
Start date
2018-02-23
Completion date
2022-11-07
Last updated
2025-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvar Vestibulitis, Vulvodynia, Vulvodynia, Generalized

Keywords

Vulvar Pain, Dyspareunia

Brief summary

This study evaluates acupuncture for the treatment of vulvodynia; specifically if it reduces vulvar pain and pain with intercourse. It also examines how long the effect of acupuncture lasts in women with vulvodynia. Half of the women will receive acupuncture and the other half will receive placebo acupuncture. Women who get a reduction in pain will monitor there pain once a week for up to 12 weeks to see how long the acupuncture effect lasts.

Detailed description

The investigators' goal is to demonstrate the effects of acupuncture for the treatment of vulvodynia. Up to 14 million American women have vulvodynia, a debilitating pain syndrome characterized by pain (burning, irritation, stinging or rawness) in the vulva and dyspareunia that renders sexual intercourse virtually impossible and leaves these women desperate for relief. Not only are women in pain, but they often lose their partners or have relationship difficulties due to their inability to have sexual intercourse. No therapies have been proven efficacious and rapid pain relief is unpredictable and rarely possible. After exhausting Western Medicine options, these women often turn to acupuncture. But in contrast to other pain conditions, there have been no acupuncture sham control studies of vulvodynia. Only four studies, including one of the investigators', provide some evidence of the effect of acupuncture on vulvodynia. In three, single-group acupuncture studies, women had less pain, better quality of life, improved sexual health, and improved mental health. The investigators' randomized wait-list controlled pilot study of 36 women with vulvodynia showed great promise. The investigators found a statistically significant and clinically meaningful reduction in vulvar pain and dyspareunia, and an increase in overall sexual function after a 5-week, 13-needle, 10 session acupuncture protocol. This newly developed, standardized acupuncture treatment protocol is the first breakthrough in the treatment of this puzzling disorder. It includes acupuncture points that relieve pain in the genitals. The results of the investigators' initial pilot study provided the first evidence from a two-group design that the acupuncture protocol could reduce pain intensity, pain during intercourse, and increase overall sexual function. These findings, however, warrant stronger evidence to support the inference that the effect is indeed due to the acupuncture since ours or no other study included a sham control or provided follow-up data beyond immediate posttest, which means that the duration of the acupuncture effect is unknown. The investigators' recent feasibility study paves the way to overcome this gap by use of double-blind acupuncture needles. Findings from these two studies support the investigators' proposal for the world's first double-blind randomized controlled trial (RCT) of acupuncture for vulvodynia while exploring its duration of effect. The investigators propose a phase 2 double-blind, pretest/posttest RCT to compare effects of penetrating needles or the skin touch placebo needles on vulvar pain in our 13-needle, 10-session acupuncture treatment protocol. A sample of 130 women, with a diagnosis of vulvodynia, either generalized or provoked vestibulodynia, 18 to 45 years of age will be recruited from clinical and community settings and 80 subjects are expected to complete the study. Stratified by type of vulvodynia, participants will be randomized 1:1 either to the penetrating needle group or the skin touch placebo needle group. These double-blind needles will provide a strong sham procedure to mask both the acupuncturist and subject to the type of needle used for the 10-treatment protocol. Specific aims are to: Aim 1. Compare the penetrating needle group and the skin touch placebo needle group for effects on the: (a) primary outcome: vulvar pain (PAINReportIt® average pain intensity, 0-10), and (b) secondary outcomes: dyspareunia (FSFI dyspareunia) and sexual function (FSFI total). The investigators hypothesize that controlling for baseline values, at posttest there will be statistically significant less vulvar pain (primary) and dyspareunia and better sexual function in the penetrating needle group compared to the skin touch placebo group. Aim 2. In participants with a clinically meaningful reduction in pain intensity (at least 1.5 points) at posttest compared to pretest, describe the duration of the acupuncture treatment and placebo effects weekly until pain returns to pretest or up to 12 weeks after posttest. The investigators will describe the variability over time in vulvar pain intensity (0-10) after a tampon insertion-removal stimulus and thereby explore the duration of the effect by intervention group, vulvodynia subgroups, and demographic subgroups (e.g., age, race, occupation). These findings will provide insights to guide future research on initial and maintenance acupuncture for vulvodynia.

Interventions

Active Acupuncture two times per week for 5 weeks

OTHERPlacebo Acupuncture

Placebo Acupuncture two times per week for 5 weeks

Sponsors

University of Florida
CollaboratorOTHER
University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. a previous diagnosis of generalized vulvodynia or provoked vestibulodynia 2. 18 to 45 years old 3. a pain now score 4 or higher with tampon insertion and removal performed at the initial screening exam 4. speak and read English Exclusionary Criteria: 1. infectious conditions of the vulva/vagina 2. inflammatory conditions of the vulva/vagina 3. neoplastic disorders of the vulva/vagina 4. neurologic disorders of the vulva/vagina 5. trauma to the genitals 6. iatrogenic conditions of the genitals 7. hormonal deficiencies 8. co-morbid pelvic pain conditions (to avoid confounding pain outcomes) such as pelvic inflammatory disease and documented history of endometriosis 9. menopause Patients may have a history of but not have active in the last 6 months migraine headaches, temporomandibular joint disease (TMJ), irritable bowel syndrome (IBS), interstitial cystitis, painful bladder syndrome, or fibromyalgia. \-

Design outcomes

Primary

MeasureTime frameDescription
Average Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).baseline and after the 10th acupuncture treatment week 5The subject calls the pain intensity a number ranging between the minimum value, 0 and 10, the maximum value. Zero represents no pain and 10 representspain as bad as it could be. Higher scores mean more pain. The PINS will include three items (pain now, least and worst pain in the past 24 hours), which are used to calculate the average of pain intensity. The PINS with the three items and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire.

Secondary

MeasureTime frameDescription
Dyspareunia Subscale of the Female Sexual Function Index (FSFI)baseline and after the 10th acupuncture treatment week 5The Dyspareunia Subscale of the FSFI measures pain with sexual intercourse. The FSFI consists of three items scored using a scale ranging from zero to five. The scores of the three items are then summed and multiplied by a factor of 0.4, resulting in a minimum score of 0 and a maximum score of 6.0, with higher scores indicating less pain with sexual intercourse.
Total Score of the Female Sexual Function Index (FSFI)baseline and after the 10th acupuncture treatment week 5The FSFI is a 19-item, multi-dimensional, self-report measure that measures overall sexual function from six domains of sexual response: desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. The six subscale scores are measured on a scale of 0-5 for each item. Individual item responses from each of the 6 domains are added together to achieve a domain score and are each multipled by a factor (desire, 0.6; arousal, 0.3; lubrication, 0.3; orgasm, 0.4; satisfaction, 0.4; and dyspareunia, 0.4). These final domain scores are summed to obtain the Total Score of the FSFI, ranging from 2.0 to 36.0, with higher scores indicating better overall sexual function.
Vulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).after the 10th acupuncture treatment weekly up to 12 weeks post last acupuncture treatment.The subject calls the pain intensity a number between 0, the minimum value and 10, the maximum value. Zero is no pain and 10 is pain as bad as it could be. Higher scores indicate a worse outcome. The PINS will include one item (vulvar pain intensity). The PINS with vulvar pain intensity and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire.

Countries

United States

Participant flow

Recruitment details

Four-hundred and fifty women were assessed for eligibility of which 290 did not meet eligibility criteria and 71 declined to participate. Eighty-nine participants were enrolled between February 2018 and September 2022. Participants were recruited from community settings as well as from medical clinics throughout the Chicagoland area, from healthcare provider referrals, and from the National Vulvodynia Association website.

Pre-assignment details

No participants were excluded after randomization and assignment to the groups.

Participants by arm

ArmCount
Experimental: Active Acupuncture
Active Acupuncture two times per week for 5 weeks Active Acupuncture: Active Acupuncture two times per week for 5 weeks
45
Placebo Acupuncture
Placebo Acupuncture two times per week for 5 weeks Placebo Acupuncture: Placebo Acupuncture two times per week for 5 weeks
44
Total89

Baseline characteristics

CharacteristicExperimental: Active AcupunctureTotalPlacebo Acupuncture
Age, Continuous29.0 years
STANDARD_DEVIATION 8.25
30.2 years
STANDARD_DEVIATION 8.34
31.4 years
STANDARD_DEVIATION 8.35
Ethnicity (NIH/OMB)
Hispanic or Latino
10 Participants18 Participants8 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
34 Participants69 Participants35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants2 Participants1 Participants
Race (NIH/OMB)
Asian
3 Participants7 Participants4 Participants
Race (NIH/OMB)
Black or African American
2 Participants5 Participants3 Participants
Race (NIH/OMB)
More than one race
2 Participants3 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants10 Participants4 Participants
Race (NIH/OMB)
White
31 Participants62 Participants31 Participants
Region of Enrollment
United States
45 Participants89 Participants44 Participants
Sex: Female, Male
Female
45 Participants89 Participants44 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 450 / 44
other
Total, other adverse events
0 / 450 / 44
serious
Total, serious adverse events
0 / 450 / 44

Outcome results

Primary

Average Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).

The subject calls the pain intensity a number ranging between the minimum value, 0 and 10, the maximum value. Zero represents no pain and 10 representspain as bad as it could be. Higher scores mean more pain. The PINS will include three items (pain now, least and worst pain in the past 24 hours), which are used to calculate the average of pain intensity. The PINS with the three items and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire.

Time frame: baseline and after the 10th acupuncture treatment week 5

Population: Participants receiving active acupuncture and placebo acupuncture

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: Active AcupunctureAverage Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Baseline3.90 score on a scaleStandard Deviation 2.39
Experimental: Active AcupunctureAverage Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).After the 10th acupuncture treatment week 52.48 score on a scaleStandard Deviation 2.11
Placebo AcupunctureAverage Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Baseline3.51 score on a scaleStandard Deviation 2.31
Placebo AcupunctureAverage Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).After the 10th acupuncture treatment week 52.22 score on a scaleStandard Deviation 2.09
p-value: 0.70295% CI: [-0.76, 0.51]ANCOVA
Secondary

Dyspareunia Subscale of the Female Sexual Function Index (FSFI)

The Dyspareunia Subscale of the FSFI measures pain with sexual intercourse. The FSFI consists of three items scored using a scale ranging from zero to five. The scores of the three items are then summed and multiplied by a factor of 0.4, resulting in a minimum score of 0 and a maximum score of 6.0, with higher scores indicating less pain with sexual intercourse.

Time frame: baseline and after the 10th acupuncture treatment week 5

Population: Participants receiving active acupuncture and placebo acupuncture.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: Active AcupunctureDyspareunia Subscale of the Female Sexual Function Index (FSFI)Baseline1.22 score on a scaleStandard Deviation 0.89
Experimental: Active AcupunctureDyspareunia Subscale of the Female Sexual Function Index (FSFI)after the 10th acupuncture treatment week 51.61 score on a scaleStandard Deviation 1.76
Placebo AcupunctureDyspareunia Subscale of the Female Sexual Function Index (FSFI)Baseline1.38 score on a scaleStandard Deviation 1.16
Placebo AcupunctureDyspareunia Subscale of the Female Sexual Function Index (FSFI)after the 10th acupuncture treatment week 51.83 score on a scaleStandard Deviation 1.82
p-value: 0.7795% CI: [-0.58, 0.79]ANCOVA
Secondary

Total Score of the Female Sexual Function Index (FSFI)

The FSFI is a 19-item, multi-dimensional, self-report measure that measures overall sexual function from six domains of sexual response: desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. The six subscale scores are measured on a scale of 0-5 for each item. Individual item responses from each of the 6 domains are added together to achieve a domain score and are each multipled by a factor (desire, 0.6; arousal, 0.3; lubrication, 0.3; orgasm, 0.4; satisfaction, 0.4; and dyspareunia, 0.4). These final domain scores are summed to obtain the Total Score of the FSFI, ranging from 2.0 to 36.0, with higher scores indicating better overall sexual function.

Time frame: baseline and after the 10th acupuncture treatment week 5

Population: Participants receiving active acupuncture and placebo acupuncture.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: Active AcupunctureTotal Score of the Female Sexual Function Index (FSFI)Baseline15.9 score on a scaleStandard Deviation 7.05
Experimental: Active AcupunctureTotal Score of the Female Sexual Function Index (FSFI)After the 10th acupuncture treatment week 517.0 score on a scaleStandard Deviation 8.29
Placebo AcupunctureTotal Score of the Female Sexual Function Index (FSFI)Baseline17.4 score on a scaleStandard Deviation 5.92
Placebo AcupunctureTotal Score of the Female Sexual Function Index (FSFI)After the 10th acupuncture treatment week 519.3 score on a scaleStandard Deviation 7.71
p-value: 0.43695% CI: [-1.76, 4.09]ANCOVA
Secondary

Vulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).

The subject calls the pain intensity a number between 0, the minimum value and 10, the maximum value. Zero is no pain and 10 is pain as bad as it could be. Higher scores indicate a worse outcome. The PINS will include one item (vulvar pain intensity). The PINS with vulvar pain intensity and standardized instructions is part of PAINReportIt® which is an electronic version of the 1970 version of the McGill Pain Questionnaire.

Time frame: after the 10th acupuncture treatment weekly up to 12 weeks post last acupuncture treatment.

Population: Participants receiving active acupuncture and placebo acupuncture that entered the Duration of Effect phase. Participants with a clinically meaningful reduction in pain intensity (at least 1.5 points) at the 10th acupuncture treatment compared to pretest, will measure Vulvar Pain Intensity weekly until pain returns to pretest or up to 12 weeks after the 10th acupuncture treatment.

ArmMeasureGroupValue (MEAN)Dispersion
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 63.88 score on a scaleStandard Deviation 2.68
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 94.00 score on a scaleStandard Deviation 2.83
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 43.23 score on a scaleStandard Deviation 2.09
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 103.50 score on a scaleStandard Deviation 1.78
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 73.22 score on a scaleStandard Deviation 1.99
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 112.89 score on a scaleStandard Deviation 2.57
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 54.55 score on a scaleStandard Deviation 2.54
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 125.40 score on a scaleStandard Deviation 2.19
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 14.19 score on a scaleStandard Deviation 2.33
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 82.67 score on a scaleStandard Deviation 1.8
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 23.37 score on a scaleStandard Deviation 2.5
Experimental: Active AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 33.79 score on a scaleStandard Deviation 2.68
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 82.79 score on a scaleStandard Deviation 1.57
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 33.16 score on a scaleStandard Deviation 1.98
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 43.23 score on a scaleStandard Deviation 2.39
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 122.64 score on a scaleStandard Deviation 1.22
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 53.13 score on a scaleStandard Deviation 1.63
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 63.33 score on a scaleStandard Deviation 1.78
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 73.84 score on a scaleStandard Deviation 2.48
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 23.68 score on a scaleStandard Deviation 2.31
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 92.32 score on a scaleStandard Deviation 0.99
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 102.77 score on a scaleStandard Deviation 1.59
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 113.04 score on a scaleStandard Deviation 1.39
Placebo AcupunctureVulvar Pain Intensity Will be Measured With the Pain Intensity Numbers Scale (PINS).Week 12.60 score on a scaleStandard Deviation 2.09
Comparison: Goal was to assess duration of effect among those who showed a response to the intervention (1.5 or greater decrease in PIN).p-value: 0.01795% CI: [1.13, 6.54]Log Rank

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026